Saturday 17 October 2026
Export SCYX’s income statement to Excel — free account
SCYNEXIS, Inc.
SCYX Healthcare Drug Manufacturers Specialty & Generic
SCYNEXIS, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $20.6 million, up 449.9% from fiscal 2024. In the quarter to June 2026, revenue fell 8.56%, EPS grew 156.3% and free cash flow fell 98.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.67
0.24
−6.14%
Follow SCYX
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 1.56 | 0.00 | 0.00 |
Piotroski F-Score |
3 | 4 | 3 | 2 | — | — | — | 7 | 2 | 5 |
P/S ratio |
251.79 | 237.26 | 82.31 | 274.37 | — | 12.23 | 12.05 | 0.75 | 15.67 | 1.53 |
Altman Z-Score |
(3.17) | (5.72) | (5.98) | (7.91) | — | (3.58) | (8.59) | 1.04 | (5.50) | (7.02) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 1.76 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(5.38) | (12.55) | (10.02) | (16.18) | — | (7.40) | (17.61) | 0.55 | (11.19) | (13.88) |
Beneish M-Score |
— | (2.62) | 22.88 | — | — | — | 2.24 | — | — | — |
P/Operating CF |
(14.21) | (11.82) | (3.49) | (3.79) | — | (6.31) | (2.69) | (13.67) | (5.93) | 1.72 |
P/B ratio |
1.86 | 2.85 | 0.68 | 3.96 | — | 3.90 | 18.98 | 1.45 | 1.07 | 0.64 |
Price to Tangible BV |
1.86 | 2.85 | 0.68 | 3.96 | — | 4.00 | 21.72 | 1.45 | 1.07 | 0.64 |
EV/Sales |
137.65 | 123.48 | (2.44) | 76.22 | — | 7.36 | 7.71 | 0.31 | 6.62 | 0.84 |
EV/EBITDA |
0.00 | 0.00 | 0.02 | 0.00 | — | 0.00 | 0.00 | 0.57 | 0.00 | 0.00 |
EV/Operating CF |
(1.21) | (1.29) | 0.02 | (0.37) | — | (1.78) | (0.49) | 0.72 | (1.03) | (3.28) |
EV/FCF |
(1.20) | (1.29) | 0.02 | (0.37) | — | (1.74) | (0.49) | 0.72 | (1.03) | (3.27) |
Quick Ratio |
15.82 | 4.35 | 8.67 | 4.40 | 3.63 | 7.74 | 4.29 | 4.58 | 2.48 | 7.00 |
Current Ratio |
15.96 | 4.43 | 8.76 | 4.76 | 3.72 | 8.03 | 4.49 | 6.26 | 3.00 | 7.04 |
Net Debt/EBITDA |
1.60 | 1.13 | 0.99 | 0.77 | 1.54 | 1.08 | 0.34 | (0.82) | 1.69 | 2.54 |
Debt/Assets |
23.84% | 31.96% | 28.37% | 20.16% | 16.11% | 33.67% | 51.70% | 9.47% | 0.00% | 0.00% |
Debt/Equity |
0.41 | 0.68 | 0.48 | 0.89 | 0.73 | 0.98 | 14.04 | 0.17 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.12 | 0.05 | 1.30 | 0.03 | 0.28 |
Operating CF/Net income |
0.98 | 0.98 | 2.27 | 0.71 | 0.89 | 1.66 | 1.27 | 0.90 | 1.13 | 0.61 |
Capex/Depreciation |
(0.21) | 0.00 | (1.17) | 0.00 | 0.00 | (0.70) | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Coverage |
(79.25) | (18.09) | (18.44) | (49.62) | (43.31) | (22.87) | (16.50) | 23.22 | (44.83) | (92.91) |
| (78.13%) | (89.14%) | (47.38%) | (243.47%) | (309.57%) | (102.68%) | (282.34%) | 175.97% | (33.25%) | (16.48%) | |
| (54.99%) | (47.44%) | (25.18%) | (97.37%) | (69.12%) | (29.56%) | (60.50%) | 62.01% | (19.44%) | (11.50%) | |
ROIC |
0.00% | 0.00% | (894.48%) | 0.00% | 0.00% | 0.00% | 0.00% | 437.60% | 0.00% | (108.43%) |
Return on Tangible Assets |
(53.93%) | (71.97%) | (27.04%) | (128.51%) | (76.53%) | (34.32%) | (102.22%) | 78.12% | (44.27%) | (24.85%) |
Average Days of Receivables |
330.91 | 356.48 | 9,561.01 | 0.00 | 0.00 | 23.87 | 150.63 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
7,811.67% | 7,130.74% | 8,389.11% | 31,730.58% | 0.00% | 180.60% | 535.44% | 22.07% | 704.89% | 108.15% |
Selling, General and Administrative Expense of Revenue |
3,112.06% | 3,210.51% | 3,377.43% | 8,800.00% | 0.00% | 379.21% | 1,236.71% | 14.93% | 385.96% | 69.88% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
470.82% | 646.69% | 706.61% | 1,510.74% | 0.00% | 15.86% | 72.40% | 1.87% | 89.32% | 13.84% |
Graham Net Nets |
0.53 | 0.34 | 1.40 | 0.16 | — | 0.19 | (0.09) | 0.44 | 0.62 | 0.97 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 55.84 | 0.00 | 0.00 |
Earnings Yield |
(46.54%) | (40.79%) | (62.77%) | (106.59%) | — | (19.51%) | (96.53%) | 64.25% | (36.36%) | (26.88%) |
Free Cash Flow Yield |
(45.40%) | (40.27%) | (136.56%) | (75.80%) | — | (34.63%) | (130.22%) | 56.87% | (40.93%) | (16.78%) |
Revenue per Share |
1.08 | 0.77 | 0.47 | 0.17 | 0.00 | 3.99 | 0.96 | 23.43 | 0.62 | 3.30 |
Operating CF per Share |
(123.38) | (73.45) | (51.63) | (54.38) | (36.83) | (16.54) | (15.00) | 10.06 | (3.96) | (0.85) |
Capex per Share |
(0.11) | (0.01) | (1.03) | 0.00 | 0.00 | (0.36) | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(123.50) | (73.46) | (52.66) | (54.38) | (36.83) | (16.90) | (15.00) | 10.06 | (3.96) | (0.85) |
Cash per Share |
246.26 | 131.30 | 80.59 | 69.06 | 69.43 | 31.68 | 13.81 | 12.50 | 9.85 | 6.43 |
Shareholders Equity per Share |
146.36 | 64.04 | 56.92 | 18.40 | 16.98 | 12.51 | 0.61 | 12.20 | 9.08 | 7.91 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
146.36 | 64.04 | 56.92 | 18.40 | 16.98 | 12.51 | 0.61 | 12.20 | 9.08 | 7.91 |
Free Cash Flow |
(29.38) | (24.56) | (28.89) | (38.12) | (49.36) | (55.73) | (79.89) | 60.16 | (24.01) | (5.28) |
Working Capital |
55.61 | 34.82 | 45.59 | 41.39 | 71.81 | 95.76 | 61.44 | 85.81 | 48.08 | 34.64 |
Capital Expenditures |
(0.03) | 0.00 | (0.56) | — | 0.00 | (1.17) | (0.01) | — | — | — |
Net Current Asset Value |
34.35 | 20.52 | 29.52 | 8.14 | 18.43 | 30.80 | (5.52) | 46.67 | 36.62 | 30.72 |
EV/EBIT |
0.00 | 0.00 | 0.02 | 0.00 | — | 0.00 | 0.00 | 0.60 | 0.00 | 0.00 |
Capex to Sales |
0.11 | 0.01 | 2.20 | 0.00 | 0.00 | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 1.46 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.00 | 110.25 | 0.93 | 3.17 | 4.40 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cash ROIC |
(27.29%) | (30.71%) | (31.91%) | (52.34%) | (37.30%) | (29.95%) | (65.39%) | 37.63% | (20.91%) | (5.90%) |
Accounts Receivable Turnover |
0.54 | 1.06 | 0.07 | 0.00 | 0.00 | 7.04 | 3.44 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.05 | 0.09 | 2.39 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | 0.00 | 0.00 | 0.92 | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 5,588.23 | 9,181.15 | 3,450.64 | 167.01 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | 0.00 | 541.65 | 522.51 | 0.00 | — | — |
Average Receivables |
0.48 | 0.24 | 3.49 | — | 4.80 | 1.87 | 1.48 | — | — | — |
Average Payables |
1.41 | 3.01 | 3.74 | 5.42 | 5.91 | 6.24 | 6.89 | 6.54 | 5.86 | 3.40 |
Average Inventory |
— | — | — | — | — | — | 0.68 | — | — | — |
Average Assets |
54.53 | 52.82 | 49.51 | 55.16 | 79.84 | 111.19 | 103.82 | 108.11 | 109.53 | 74.84 |
Average Common Equity |
38.38 | 28.11 | 26.32 | 22.06 | 17.83 | 32.01 | 22.25 | 38.10 | 64.02 | 52.23 |
Columns are period end dates